Navigation Links
VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
Date:10/13/2009

al companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009, each on file with the SEC.

    • All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

    SOURCE VIA Pharmaceuticals, Inc.


    '/>"/>
    SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine technology :

    1. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    2. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
    3. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    4. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
    5. Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
    6. ADVENTRX Pharmaceuticals Announces Closing of Financing
    7. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
    8. Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
    9. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
    10. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
    11. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/19/2009)...Newswire/ -- As the seasons change, another season...on preparing yourself. ,, Listen to this report...: ,, http://inr.mediaseed.tv/oneClip_C/?feed...nk is a division of The NewsMarket. Registered jo...and photos at http://www.thenewsmarket.com . ,...
    (Date:11/19/2009)... 19 Mach 7 Technologies, a globa...age management solutions, and QStar Technologies h...- neutral archive solution through their common US...national leader in providing digital image distrib...try. Under the agreement, Data Distributing will ...
    (Date:11/19/2009)...19 Impliant, Inc., a developer of ...pinal fusion surgery, announced today that it has ...as the Vice President of Clinical and Regulatory A...gi-bin/prnh/20080527/NETU060LOGO ) ,, Mr. Rol...rience in the spinal and medical device field to I...
    Breaking Medicine Technology:Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Stories we tell about national trauma reflect our psychological well being 52964 1Stories we tell about national trauma reflect our psychological well being 52964 2Stories we tell about national trauma reflect our psychological well being 52964 3Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 1Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 2Wildfires set to increase 50 percent by 2050 9392 1Wildfires set to increase 50 percent by 2050 9392 2
    ... - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) tod... INNO-406, a potent oral dual Bcr-Abl and Lyn-kina...tolerant chronic,myelogenous leukemia, will be pre...arch Annual Meeting. The meeting takes place April...in Los Angeles,California., Information related t...
    ...n Valopicitabine Combined,with an Investigational ...07 /PRNewswire-FirstCall/ --,Idenix Pharmaceutical... studies of the novel combination of valopicitabin...s(R)) in both treatment-naive,and treatment- exper...n of the hepatitis C virus (HCV). These data, as w...
    Other Medicine Technology:Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7
    (Date:11/21/2009)...Newswire-USNewswire/ -- Tonight, in a partisan vot...d,s version of the government takeover of health c...d in this bill; like the public option, employer a...for elective abortion, which is the most onerous a...ovides subsidies for private plans that cover elec...
    (Date:11/21/2009)... for an unprecedented expansion of federally-funde... for preserving and protecting human life? If the ...ine Yoest ,, WASHINGTON, Nov. 21 /PRNewswire-...esident and CEO Dr. Charmaine Yoest responded to t...wing statement: ,, "This was a pro-abortion vo...
    (Date:11/21/2009)...RNewswire-USNewswire/ -- A regional initiative lau...ver blindness) in the Americas has substantially r...rs, as evidenced by a 31% decrease in the number o...n six endemic countries. Results were reported to...iety of Tropical Medicine and Hygiene (ASTMH). ,...
    (Date:11/21/2009)...2009 Test Test Test Test... Test Test Test Test Test,Test Test Test Test Test...,Test Test Test Test Test Test Test Test Test Test...t More test More test More test More test,More tes...t More test More,test More test , , Please ign...
    (Date:11/21/2009)...e medical apparel company launches men,s lab coats... San Clemente, Calif. (PRWEB) November 21, 2009...pparel, today announced the launch of its men,s la...ading international trade fair for the medical ind...rates its men,s collection with three varying lab ...
    Breaking Medicine News(10 mins):Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3
    ...s called for curtailing comparative advertisements...d producers//. Suitable amendments should be made ...han, in addition to other media and channels, and ... the products of a competitor are concerned. Compa...
    ...years the timings for the last order for drinks ha...he clock drinking. Thousands of revelers up and ...ink in pubs and bars after midnight. // No major ...nduced violence on the streets of England and Wale...
    ...cough/Pertussis have tripled in Idaho (central) an...selves revaccinated against infectious respiratory...y by central district health department so far in ... the 10 year average period of 23 cases/year. ...
    ...charge as he was suffering from Parasomnia, but th... to have her case against him in Canadian Supreme ... woman after a party when they were both in a drun...ertain things without knowing what they are during...
    ...ed survey indicates that the ageing population in ... eats// three meals a day and most are non-vegetar... over 60 years in Kerala eat three meals a day, ac... population. Headed by S. Irudayarajan of the ...
    ...esearch team comprising Scott Belcher, PhD, did a ...ain tissue// 'at surprisingly low doses.' Wo...he first to show that oestrogen’s rapid signalling... 'BPA molecules are linked into polymers used...
    Other Medicine News:Health News:Three meals daily Keeps 'Kerala's elderly Healthy 2Health News:Food packaging with Bisphenol A damages the brain 2
    Short-Sleeve Bolero
    Breast Wrap II
    Breast Wrap
    Sub Pectoral Breast Augmentation Wrap
    Medicine Products: